Floatz logo

H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa

Urothelial Carcinoma

Explore 163 assets in Urothelial Carcinoma →
Floatz Rating
C39/100
Confidence
Indicative
v0.2
Sponsor
Genentech, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05581004CT.gov
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urothelial Carcinoma

AssetSponsorPhaseRating
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa (this asset)Genentech, Inc.P1C · 39
CyclophosphamideBeijing BiotechP3BB
DurvalumabAlliance for Clinical Trials in OncologyP3BB
Cis-Diamminedichloroplatinum IiNagoya UniversityP3BB
PembrolizumabSutro Biopharma, Inc.P3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncP2/3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, DimerEli Lilly and CompanyP3BB
RetifanlimabIncyte CorporationP2BB
DocetaxelNuCana plcP3BB

+42 more in the Urothelial Carcinoma cohort

Other indications for H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa

IndicationSponsorPhaseRating
Nonpapillary Renal Cell Carcinoma—P1CC · 43
Triple-Negative Breast Carcinoma—P1CC · 41
Head And Neck Squamous Cell Carcinoma—P1CC · 41

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa in Urothelial Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/h-gamma1-heavy-chain-humanized-1-449-vh-homo-sapiens-ighv3-2301-816-ighd-ighj302-917-m123t-114-cdr-imgt-8713-26-3351-5796-108-1-119-homo-sapiens-ighg103v-100-g1m3g1m17-ng1m1-ch1-k120-ch3-e12-m14-ch1-r120k-216-120-217-hinge-1-15-218-232-ch2-233-342-ch3-e12-358-m14-360-343-447-chs-448-449-120-449-222-218-disulfide-with-l-kappa-light-chain-humanized-1-218-vkappa-homo-sapiens-igkv1-3301-878-igkj401-100-cdr-imgt-6313-27-3250-5289-101-1-111-homo-sapiens-igkc01-100-km3-a451-v101-c-kappaa451-157-v101-195-112-218-dimer-228-228231-231-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-glycoform-alfa-urothelial-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →